{
    "eid": "2-s2.0-85147658367",
    "title": "Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants",
    "cover-date": "2023-04-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Microbiology (medical)",
            "@code": "2726",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Booster strategy",
        "COVID-19",
        "Immune response",
        "Vaccine"
    ],
    "authors": [
        "Suvimol Niyomnaitham",
        "Anan Jongkaewwattana",
        "Atibordee Meesing",
        "Nawamin Pinpathomrat",
        "Sira Nanthapisal",
        "Nattiya Hirankarn",
        "Sarawut Siwamogsatham",
        "Suppachok Kirdlarp",
        "Romanee Chaiwarith",
        "Saranath Lawpoolsri",
        "Supranee Phanthanawiboon",
        "Arunee Thitithanyanont",
        "Pokrath Hansasuta",
        "Sansanee Chaiyaroj",
        "Punnee Pitisuttithum"
    ],
    "citedby-count": 2,
    "ref-count": 29,
    "ref-list": [
        "Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization",
        "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection",
        "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",
        "Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile",
        "Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials",
        "Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality",
        "Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells",
        "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",
        "Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern. Alpha: Delta, Beta) in Thai healthcare workers",
        "Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: an open-label randomized study in healthy Thai adults",
        "Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)",
        "Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials",
        "Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England",
        "Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants",
        "Effects of a prolonged booster interval on neutralization of Omicron variant",
        "Protection by a fourth dose of BNT162b2 against Omicron in Israel",
        "Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron",
        "Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial",
        "Omicron BA.4/BA.5 escape neutralizing immunity by BA.1 infection",
        "Real-world effectiveness of mix-and-match vaccine regimens against SARS-CoV-2 Delta variant in Thailand: a nationwide test-negative matched case-control study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199573",
            "affilname": "Faculty of Tropical Medicine, Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199573",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60026046",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nakhon Pathom",
            "@id": "60012718",
            "affilname": "Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012718",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60032250",
            "affilname": "Faculty of Medicine, Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032250",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hatyai",
            "@id": "60025527",
            "affilname": "Faculty of Medicine, Prince of Songkia University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025527",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60015887",
            "affilname": "Faculty of Medicine Ramathibodi Hospital, Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015887",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60013939",
            "affilname": "Faculty of Medicine, Thammasat University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013939",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60011947",
            "affilname": "Thailand National Center for Genetic Engineering and Biotechnology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011947",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "CM Clinical Trial Unit Faculty of Medicine, Chiang Mai University",
        "Chakri Naruebodindra Medical Institute",
        "Clinixir Co. Ltd",
        "Maha Chakri Sirindhorn Clinical Research Center",
        "National Higher Education, Science, Research and Innovation Policy Council, Thailand",
        "Siriraj Institute of Clinical Research, Faculty of Medicine, Mahidol University",
        "Thammasart University",
        "Chulalongkorn University",
        "Khon Kaen University",
        "Mahidol University",
        "Prince of Songkla University"
    ]
}